[go: up one dir, main page]

CY1110989T1 - Χρηση 3-(4-αμινο-1-οξο-1,3-διυδρο-ισοϊνδολ-2-υλο)-πιπεριδινο-2,6-διονης για την αντιμετωπιση λεμφωματων κυτταρων του μανδυα - Google Patents

Χρηση 3-(4-αμινο-1-οξο-1,3-διυδρο-ισοϊνδολ-2-υλο)-πιπεριδινο-2,6-διονης για την αντιμετωπιση λεμφωματων κυτταρων του μανδυα

Info

Publication number
CY1110989T1
CY1110989T1 CY20101101137T CY101101137T CY1110989T1 CY 1110989 T1 CY1110989 T1 CY 1110989T1 CY 20101101137 T CY20101101137 T CY 20101101137T CY 101101137 T CY101101137 T CY 101101137T CY 1110989 T1 CY1110989 T1 CY 1110989T1
Authority
CY
Cyprus
Prior art keywords
treatment
isoindol
piperidino
dione
dihydro
Prior art date
Application number
CY20101101137T
Other languages
English (en)
Inventor
Jerome B Zeldis
Original Assignee
Celgene Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38691762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1110989(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Corporation filed Critical Celgene Corporation
Publication of CY1110989T1 publication Critical patent/CY1110989T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η αντιμετώπιση, πρόληψη ή διαχείριση λεμφωμάτων από κύτταρα του μανδύα με χορήγηση μιας ανοσοδιαμορφωτικής ένωσης της εφεύρεσης γνωστής ως Revlimid® ή λεναλιδομίδη γνωστοποιούνται. Η εφεύρεση περαιτέρω σχετίζεται με τη χρήση αυτής της ένωσης με χημειοθεραπεία, θεραπεία με ακτινοβολία, ορμονική θεραπεία, βιολογική θεραπεία ή ανοσοθεραπεία για την αξιούμενη αγωγή. Φαρμακευτικές συνθέσεις και απλές μοναδιαίες δοσολογικές μορφές κατάλληλες για χρήση στην εφεύρεση επίσης γνωστοποιούνται.
CY20101101137T 2006-08-03 2010-12-10 Χρηση 3-(4-αμινο-1-οξο-1,3-διυδρο-ισοϊνδολ-2-υλο)-πιπεριδινο-2,6-διονης για την αντιμετωπιση λεμφωματων κυτταρων του μανδυα CY1110989T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83575206P 2006-08-03 2006-08-03
EP07811048A EP2046331B1 (en) 2006-08-03 2007-08-02 Use of 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment of mantle cell lymphomas

Publications (1)

Publication Number Publication Date
CY1110989T1 true CY1110989T1 (el) 2015-06-11

Family

ID=38691762

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101101137T CY1110989T1 (el) 2006-08-03 2010-12-10 Χρηση 3-(4-αμινο-1-οξο-1,3-διυδρο-ισοϊνδολ-2-υλο)-πιπεριδινο-2,6-διονης για την αντιμετωπιση λεμφωματων κυτταρων του μανδυα

Country Status (26)

Country Link
US (7) US20080038263A1 (el)
EP (1) EP2046331B1 (el)
JP (2) JP5465005B2 (el)
KR (2) KR20140082859A (el)
CN (2) CN102908346A (el)
AR (1) AR062265A1 (el)
AT (1) ATE486601T1 (el)
AU (1) AU2007282027B2 (el)
CA (2) CA2659774C (el)
CL (1) CL2007002218A1 (el)
CY (1) CY1110989T1 (el)
DE (1) DE602007010303D1 (el)
DK (1) DK2046331T3 (el)
ES (1) ES2351069T3 (el)
HR (1) HRP20100664T1 (el)
IL (1) IL196885A (el)
ME (1) ME01937B (el)
MX (1) MX2009001268A (el)
PE (1) PE20081311A1 (el)
PL (1) PL2046331T3 (el)
PT (1) PT2046331E (el)
RS (1) RS51567B (el)
RU (1) RU2446804C2 (el)
SI (1) SI2046331T1 (el)
TW (1) TWI430797B (el)
WO (1) WO2008019065A1 (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007002218A1 (es) * 2006-08-03 2008-03-14 Celgene Corp Soc Organizada Ba Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
EA201071058A1 (ru) * 2008-03-11 2011-02-28 Др. Редди'С Лабораторис Лтд. Получение леналидомида
US20110280913A1 (en) * 2008-07-31 2011-11-17 The Ohio State University Methods and Compositions for Delivering Therapeutic Agents in the Treatment of B-Cell Related Disorders
CN103068386A (zh) * 2010-03-12 2013-04-24 细胞基因公司 使用来那度胺治疗非霍奇金淋巴瘤的方法及作为预测因子的基因和蛋白质生物标记
MX2014013256A (es) 2012-05-03 2015-01-16 Janssen R & D Ireland Formulaciones de acido poliinosinico-policitidilico (poli(i:c)) para el tratamiento de infecciones de las vias respiratorias altas.
CN104004056B (zh) * 2014-06-23 2016-08-17 王方杰 一种关于Cyclin D蛋白抑制剂多肽及其应用
CN104004060B (zh) * 2014-06-23 2016-04-13 重庆医科大学 Cyclin D蛋白抑制剂多肽及其应用
CN104031122B (zh) * 2014-06-23 2016-05-11 常州市肿瘤医院 有关Cyclin D蛋白抑制剂多肽及其应用
WO2018129533A1 (en) 2017-01-09 2018-07-12 Shuttle Pharmaceuticals, Llc Selective histone deacetylase inhibitors for the treatment of human disease
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
CN111372585A (zh) 2017-11-16 2020-07-03 C4医药公司 用于靶蛋白降解的降解剂和降解决定子
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
ES2983284T3 (es) 2018-01-09 2024-10-22 Shuttle Pharmaceuticals Inc Inhibidores selectivos de histona deacetilasa para el tratamiento de enfermedades humanas
CN111902141A (zh) 2018-03-26 2020-11-06 C4医药公司 用于ikaros降解的羟脑苷脂结合剂
CN112312904B (zh) 2018-04-16 2025-01-07 C4医药公司 螺环化合物
EP3578561A1 (en) 2018-06-04 2019-12-11 F. Hoffmann-La Roche AG Spiro compounds
EP3846800A4 (en) 2018-09-04 2022-08-24 C4 Therapeutics, Inc. Compounds for the degradation of brd9 or mth1
EP3897631A4 (en) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. TARGETED PROTEIN DEGRADATION
WO2020181232A1 (en) 2019-03-06 2020-09-10 C4 Therapeutics, Inc. Heterocyclic compounds for medical treatment
JP2023538517A (ja) 2020-08-05 2023-09-08 シーフォー セラピューティクス， インコーポレイテッド Ｒｅｔの標的分解のための化合物

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
US2845770A (en) * 1956-09-26 1958-08-05 William F Fessler Baled hay rack and carrier
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3636809A (en) * 1969-07-10 1972-01-25 Nippon Musical Instruments Mfg Stringed musical instrument
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5391485A (en) * 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
AU1531492A (en) * 1991-02-14 1992-09-15 Rockefeller University, The Method for controlling abnormal concentration tnf alpha in human tissues
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5360352A (en) * 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US20010056114A1 (en) * 2000-11-01 2001-12-27 D'amato Robert Methods for the inhibition of angiogenesis with 3-amino thalidomide
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US6228879B1 (en) * 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
US6114355A (en) * 1993-03-01 2000-09-05 D'amato; Robert Methods and compositions for inhibition of angiogenesis
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5731325A (en) * 1995-06-06 1998-03-24 Andrulis Pharmaceuticals Corp. Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents
ATE530542T1 (de) 1996-07-24 2011-11-15 Celgene Corp Amino substituierte 2-(2,6-dioxopiperidin-3-yl)- phthalimide zur verringerung der tnf-alpha-stufen
US5798368A (en) * 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
JP4214537B2 (ja) * 1996-08-12 2009-01-28 セルジーン コーポレーション 新規な免疫治療薬とこの薬物を使用してサイトカインレベルを抵減する方法
EP1586322B1 (en) * 1996-11-05 2008-08-20 The Children's Medical Center Corporation Compositions comprising thalodimide and dexamethasone for the treatment of cancer& x9;
US5955476A (en) * 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
US5874448A (en) * 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
TR200101504T2 (tr) * 1998-03-16 2002-06-21 Celgene Corporation 2-(2,6-dioksopiperidin-3-il)izoindolin türevleri, bunların hazırlanması ve enflamatuar sitokinlerin inhibitörleri olarak kullanımı.
US6673828B1 (en) * 1998-05-11 2004-01-06 Children's Medical Center Corporation Analogs of 2-Phthalimidinoglutaric acid
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US20030013739A1 (en) * 1998-12-23 2003-01-16 Pharmacia Corporation Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
AU771015B2 (en) * 1999-03-18 2004-03-11 Celgene Corporation Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels
US7182953B2 (en) * 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US6326388B1 (en) * 1999-12-21 2001-12-04 Celgene Corporation Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
CA2319872C (en) * 2000-02-02 2012-06-19 Chun-Ying Huang Pharmaceutical composition for the treatment of hepatocellular carcinoma
US20020016285A1 (en) 2000-03-17 2002-02-07 Rama Bhatt Polyglutamic acid-camptothecin conjugates and methods of preparation
MXPA02009665A (es) * 2000-03-31 2005-09-08 Celgene Corp Inhibicion de actividad de ciclooxigenasa-2.
PT1307197E (pt) 2000-05-15 2006-08-31 Celgene Corp Composicoes para o tratamento do cancro compreendendo um inibidor de topoisomerase e talidomida
US6458810B1 (en) * 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
DK1353672T3 (da) 2000-11-30 2008-01-21 Childrens Medical Center Syntese af 4-amino-thalidomidenantiomerer
US20020128228A1 (en) * 2000-12-01 2002-09-12 Wen-Jen Hwu Compositions and methods for the treatment of cancer
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
ES2338534T3 (es) * 2001-02-27 2010-05-10 The Governement Of The Usa, Represented By The Secretary Department Of Health And Human Services Analogos de talidomina como inhibidores de la angiogenesis.
US7153867B2 (en) * 2001-08-06 2006-12-26 Celgene Corporation Use of nitrogen substituted thalidomide analogs for the treatment of macular degenerator
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
CA2481387A1 (en) 2002-04-12 2003-10-23 Celgene Corporation Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
CN103494817A (zh) * 2002-05-17 2014-01-08 细胞基因公司 用于治疗和控制多发性骨髓瘤的方法及组合物
US20040091455A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
CL2004001004A1 (es) * 2003-05-19 2005-03-18 Upjohn Co Combinacion farmaceutica que comprende irinotecan y revimid para tratar el mieloma multiple.
CL2007002218A1 (es) * 2006-08-03 2008-03-14 Celgene Corp Soc Organizada Ba Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
US7893045B2 (en) * 2007-08-07 2011-02-22 Celgene Corporation Methods for treating lymphomas in certain patient populations and screening patients for said therapy

Also Published As

Publication number Publication date
CA2659774C (en) 2013-12-17
PE20081311A1 (es) 2008-09-17
KR20090034404A (ko) 2009-04-07
JP5465005B2 (ja) 2014-04-09
WO2008019065A1 (en) 2008-02-14
US20170027923A1 (en) 2017-02-02
US20200276175A1 (en) 2020-09-03
ATE486601T1 (de) 2010-11-15
DK2046331T3 (da) 2011-02-07
IL196885A (en) 2016-08-31
ME01937B (me) 2011-03-02
EP2046331B1 (en) 2010-11-03
IL196885A0 (en) 2009-11-18
US20190374529A1 (en) 2019-12-12
CN101583359B (zh) 2016-12-07
CA2836006A1 (en) 2008-02-14
PL2046331T3 (pl) 2011-04-29
TW200817004A (en) 2008-04-16
HRP20100664T1 (hr) 2011-01-31
KR101483802B1 (ko) 2015-01-19
US8741929B2 (en) 2014-06-03
US20100068206A1 (en) 2010-03-18
MX2009001268A (es) 2009-03-06
CL2007002218A1 (es) 2008-03-14
RS51567B (en) 2011-08-31
US20080038263A1 (en) 2008-02-14
RU2446804C2 (ru) 2012-04-10
AU2007282027A1 (en) 2008-02-14
AU2007282027B2 (en) 2012-08-02
AR062265A1 (es) 2008-10-29
JP2009545600A (ja) 2009-12-24
TWI430797B (zh) 2014-03-21
CA2659774A1 (en) 2008-02-14
EP2046331A1 (en) 2009-04-15
CN101583359A (zh) 2009-11-18
PT2046331E (pt) 2011-02-10
ES2351069T3 (es) 2011-01-31
US20180263968A1 (en) 2018-09-20
SI2046331T1 (sl) 2011-01-31
JP2013256514A (ja) 2013-12-26
US20140271638A1 (en) 2014-09-18
RU2009107535A (ru) 2010-09-10
CN102908346A (zh) 2013-02-06
KR20140082859A (ko) 2014-07-02
DE602007010303D1 (de) 2010-12-16

Similar Documents

Publication Publication Date Title
CY1110989T1 (el) Χρηση 3-(4-αμινο-1-οξο-1,3-διυδρο-ισοϊνδολ-2-υλο)-πιπεριδινο-2,6-διονης για την αντιμετωπιση λεμφωματων κυτταρων του μανδυα
TW200730175A (en) Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
CY1123739T1 (el) Αντισωματα anti-cd38
CY1122966T1 (el) 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου
CY1121125T1 (el) Συνθεσεις για τη θεραπευτικη αντιμετωπιση του πονου και/ή της φλεγμονης
EA201100032A1 (ru) Соединения пиридина
CY1118731T1 (el) Φαρμακευτικες συνθεσεις αλβιγλουτιδης
EA201491607A1 (ru) Модуляторы толлподобных рецепторов
EA200900155A1 (ru) Модуляторы фармакокинетических свойств лекарственных средств
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
CY1119209T1 (el) Αναστολεις κινασης τυροσινης bruton
CY1116321T1 (el) Σχημα δοσολογιας ενος αγωνιστη υποδοχεα s1p
EA201170940A1 (ru) Лечение рака с использованием комбинации бендамустина и анти-cd20-антитела
CY1110013T1 (el) Συνδυασμοι για θεραπεια πολλαπλου μυελωματος
CY1117584T1 (el) Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, cx3cr1
CL2011000957A1 (es) Compuesto derivados de isoindolina sustituidos, inhibidores de citosinas tnf-a; composicion farmaceutica; utiles en el tratamiento del cancer.
TR201818814T4 (tr) Dll4 antagonist antikorlarının ve anti-hipertansif ajanların terapötik kombinasyonu ve kullanımı.
CY1116328T1 (el) Παραγωγα 4 - αμινοπυριμιδινης και η χρηση τους ως ανταγωνιστων α2α υποδοχεων αδενοσινης
CY1114148T1 (el) Γεφυρωμενες δικυκλικες αρυλο- και γεφυρωμενες δικυκλικες etepoapyλo-υποκατεστημενες τριαζολες χρησιμες ως αναστολεις toy axl
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
CL2008002097A1 (es) Compuestos derivados de heterociclos condensados sustituidos, inhibidores de cinasa de fosfatidil-inositol-3; composicion farmaceutica; y uso en el tratamiento del cancer.
CY1114363T1 (el) Ανθελμινθικος συνδυασμος
CL2009001160A1 (es) Compuestos derivados de heterociclos nitrogenados fusionados y su composicion farmaceutica.
CL2008001946A1 (es) Compuestos derivados de imidazol, antagonistas de receptores ccr2, ccr3, ccr5; procedimiento de preparacion; y uso en el tratamiento de enfermedades vasculares perifericas.